Lapatinib in the Treatment of Hormone Receptor-Positive/ErbB2-Positive Breast Cancer [PDF]
, 2010 In women with estrogen receptor(ER)- and ErbB2(HER2)-positive breast cancer, a vicious cycle is established between ER mechanisms of action and the growth factor receptor network, leading to enhanced cell proliferation and endocrine resistance.
Bauerfeind, Ingo +2 more
core +1 more source
Human adipocytes stimulate invasion of breast cancer MCF-7 cells by secreting IGFBP-2. [PDF]
PLoS ONE, 2015 A better understanding of the effects of human adipocytes on breast cancer cells may lead to the development of new treatment strategies. We explored the effects of adipocytes on the migration and invasion of breast cancer cells both in vitro and in vivo.
Chen Wang +4 more
doaj +1 more source
Detection of Tumor Cell-Specific mRNA in the Peripheral Blood of Patients with Breast Cancer-Evaluation of Several Markers with Real-Time Reverse Transcription-PCR [PDF]
, 2013 It is widely known that cells from epithelial tumors, e. g., breast cancer, detach from their primary tissue and enter blood circulation. We show that the presence of circulating tumor cells (CTCs) in samples of patients with primary and metastatic ...
Simone Hofmann +20 more
core +1 more source
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer [PDF]
, 2022 Breast cancer; Drug safetyCàncer de mama; Seguretat dels medicamentsCáncer de mama; Seguridad de los medicamentosSacituzumab govitecan (SG) is an anti-Trop-2 antibody-drug conjugate with an SN-38 payload.
Tolaney, Sara M +6 more
core +1 more source
BMC Cancer, 2021 Background Eribulin mesylate (ERI; Halaven®) is a microtubule inhibitor approved in the United States for metastatic breast cancer patients with at least two prior chemotherapy regimens for metastatic breast cancer, and in the European Union in locally ...
Qi Zhao +7 more
doaj +1 more source
Cure in metastatic breast cancer [PDF]
memo - Magazine of European Medical Oncology, 2018 Oligometastatic disease characterizes a distinct subgroup of metastatic breast cancer patients that might benefit from different treatment strategies to achieve long-lasting remission and potentially cure. Those long-lasting remissions are reported after locoregional treatment of the primary tumor and all metastatic sites in several case series ...
Westphal, Theresa +3 more
openaire +2 more sources
Markers for the identification of late breast cancer recurrence [PDF]
, 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work ...
Cuzick, J, Sestak, I
core +1 more source
Emerging Intrinsic Therapeutic Targets for Metastatic Breast Cancer
Biology, 2023 Breast cancer is now the most common cancer worldwide, and it is also the main cause of cancer-related death in women. Survival rates for female breast cancer have significantly improved due to early diagnosis and better treatment.
Jiawei Li +7 more
doaj +1 more source
Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models [PDF]
, 2015 This research was financed in part by a Grant of the 7th Framework Program of the European Union (METOXIA project; HEALTH‐F2‐2009‐222741) and the NGI Pre- Seed grant (NWO n° 93613002).Triple negative, resistant or metastatic disease are major factors in ...
Kunkler, Ian H. +30 more
core +1 more source
HER2 testing in breast cancer: Opportunities and challenges [PDF]
, 2006 Human epidermal growth factor receptor 2 (HER2) is overexpressed in 15-25% of breast cancers, usually as a result of HER2 gene amplification. Positive HER2 status is considered to be an adverse prognostic factor. Recognition of the role of HER2 in breast
Lebeau, Annette, Annette Lebeau
core +1 more source